Characteristics of 61 patients with aCML or CNL
| . | Whole series (61) . | aCML (37) . | CNL (24) . | P . |
|---|---|---|---|---|
| Gender = % male (n) | 65.6% (40) | 67.6% (25) | 62.5% (15) | .765 |
| Age (mean, range) | 69.4 (32.9-92.5) | 68.6 (40.6-91.4) | 71.2 (33.0-92.5) | .692 |
| Median OS (mo) | 17.2 | 17.7 | 15.2 | .86 |
| Transformation to AML | 29.5% (18) | 32.4% (12) | 25% (6) | .534 |
| Median time to transformation (mo) | 14.3 | 13.6 | 15.2 | .52 |
| HSCT | 17% (9) | 25.8% (8) | 4.5% (1) | .097 |
| Cause of death | .737 | |||
| Progression | 65.6% (21) | 63.2% (12) | 69.2% (9) | |
| Bleeding | 12.5% (4) | 10.5% (2) | 15.4% (2) | |
| Other | 21.9% (7) | 26.3% (5) | 15.4 (2) | |
| Splenomegaly | 55.7% (34) | 48.6% (18) | 66.7% (16) | .263 |
| Hepatomegaly | 21.7% (10) | 14.7% (5) | 41.7% (5) | .124 |
| Cutaneous bleeding | 10.6% (5) | 8.6% (3) | 16.7% (2) | .808 |
| Mucosal bleeding | 4.3% (2) | 2.9% (1) | 8.3% (1) | 1.000 |
| Hemoglobin (g/L) | 83.32 | 85.73 | 79.81 | .669 |
| Platelets (×109/L) | 303.65 | 332.83 | 259.88 | .387 |
| WBCs (×109/L) | 62.23 | 68.15 | 52.70 | .284 |
| Neutrophils (×109/L) | 53.46 | 57.23 | 47.89 | .486 |
| Lymphocytes (×109/L) | 3.70 | 4.16 | 2.96 | .069 |
| Monocytes (×109/L) | 1.88 | 2.43 | 1.02 | .018 |
| Abnormal cytogenetics | 13.5% (7) | 19.4% (6) | 4.8% (1) | .130 |
| Mutations detected by NGS | 100% (53) | 100% (30) | 100% (23) | NA |
| Number of mutated genes (mean) | 3.47 | 3.77 | 3.09 | .118 |
| Mutated CSF3R | 59.1% (26) | 27.3% (6) | 90.9% (20) | <.001 |
| Mutated SETBP1 | 52.2% (24) | 56% (14) | 47.6% (10) | .787 |
| Mutated signaling genes | 71.7% (38) | 63.3% (19) | 82.6% (19) | .216 |
| Mutated transcription factor genes | 22.6% (12) | 30% (9) | 13.0% (3) | .258 |
| Mutated tumor suppressor genes | 1.9% (1) | 3.3% (1) | 0% (0) | 1.000 |
| Mutated epigenetic modifier genes | 88.7% (47) | 93.3% (28) | 82.6% (19) | .433 |
| Mutated splicing factor genes | 56.6% (30) | 53.3% (16) | 60.9% (14) | .788 |
| Mutated Cohesins and other genes | 17% (9) | 16.7% (5) | 17.4% (4) | 1.000 |
| . | Whole series (61) . | aCML (37) . | CNL (24) . | P . |
|---|---|---|---|---|
| Gender = % male (n) | 65.6% (40) | 67.6% (25) | 62.5% (15) | .765 |
| Age (mean, range) | 69.4 (32.9-92.5) | 68.6 (40.6-91.4) | 71.2 (33.0-92.5) | .692 |
| Median OS (mo) | 17.2 | 17.7 | 15.2 | .86 |
| Transformation to AML | 29.5% (18) | 32.4% (12) | 25% (6) | .534 |
| Median time to transformation (mo) | 14.3 | 13.6 | 15.2 | .52 |
| HSCT | 17% (9) | 25.8% (8) | 4.5% (1) | .097 |
| Cause of death | .737 | |||
| Progression | 65.6% (21) | 63.2% (12) | 69.2% (9) | |
| Bleeding | 12.5% (4) | 10.5% (2) | 15.4% (2) | |
| Other | 21.9% (7) | 26.3% (5) | 15.4 (2) | |
| Splenomegaly | 55.7% (34) | 48.6% (18) | 66.7% (16) | .263 |
| Hepatomegaly | 21.7% (10) | 14.7% (5) | 41.7% (5) | .124 |
| Cutaneous bleeding | 10.6% (5) | 8.6% (3) | 16.7% (2) | .808 |
| Mucosal bleeding | 4.3% (2) | 2.9% (1) | 8.3% (1) | 1.000 |
| Hemoglobin (g/L) | 83.32 | 85.73 | 79.81 | .669 |
| Platelets (×109/L) | 303.65 | 332.83 | 259.88 | .387 |
| WBCs (×109/L) | 62.23 | 68.15 | 52.70 | .284 |
| Neutrophils (×109/L) | 53.46 | 57.23 | 47.89 | .486 |
| Lymphocytes (×109/L) | 3.70 | 4.16 | 2.96 | .069 |
| Monocytes (×109/L) | 1.88 | 2.43 | 1.02 | .018 |
| Abnormal cytogenetics | 13.5% (7) | 19.4% (6) | 4.8% (1) | .130 |
| Mutations detected by NGS | 100% (53) | 100% (30) | 100% (23) | NA |
| Number of mutated genes (mean) | 3.47 | 3.77 | 3.09 | .118 |
| Mutated CSF3R | 59.1% (26) | 27.3% (6) | 90.9% (20) | <.001 |
| Mutated SETBP1 | 52.2% (24) | 56% (14) | 47.6% (10) | .787 |
| Mutated signaling genes | 71.7% (38) | 63.3% (19) | 82.6% (19) | .216 |
| Mutated transcription factor genes | 22.6% (12) | 30% (9) | 13.0% (3) | .258 |
| Mutated tumor suppressor genes | 1.9% (1) | 3.3% (1) | 0% (0) | 1.000 |
| Mutated epigenetic modifier genes | 88.7% (47) | 93.3% (28) | 82.6% (19) | .433 |
| Mutated splicing factor genes | 56.6% (30) | 53.3% (16) | 60.9% (14) | .788 |
| Mutated Cohesins and other genes | 17% (9) | 16.7% (5) | 17.4% (4) | 1.000 |
P for differences between aCML and CNL. Statistically significant differences are in bold.
HSCT, hematopoietic stem cell transplant.